Key result
Solid lipid nanoparticles enhance oral bioavailability and controlled release of antiplatelet therapies.
Why the study?
Improving the bioavailability of poorly absorbed drugs that are significantly degraded in the mouth is a major challenge in oral medicine.
Solid lipid nanoparticles represent a promising drug delivery system to enhance the oral bioavailability, stability, and targeted delivery of antiplatelet therapies in acute coronary syndrome.
Supports preclinical validation of lipid nanoparticles; leaves open whether randomized trials will confirm clinical benefits in coronary heart disease.
The application of nanoparticle technology in oral medicine has spurred substantial research endeavours to improve the solubility, permeability, and chemical stability of different pharmaceuticals. Improving the bioavailability of poorly absorbed drugs that are significantly degraded in the mouth is a major challenge in this research. The creation of solid lipid nanoparticles (SLNs) is the main topic of this review since it seems like a possible solution to these problems. We go over the stability, characterisation, and synthesis of SLNs, highlighting their potential to improve acute coronary syndrome treatment medication administration. The review also delves into the process by which antiplatelet SLNs work to prevent myocardial infarction, providing information about how they can enhance treatment results.
No takes yet. Share an insight, caveat, or question.
Lalwani et al. (2025) conducted a review in Acute coronary syndrome. Solid lipid nanoparticles (SLNs) vs. Conventional oral formulations was evaluated. Solid lipid nanoparticles enhance the oral bioavailability, stability, and controlled release of antiplatelet therapies, offering a promising strategy for improving coronary heart disease treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: